Apyx Medical is capitalizing on the GLP-1 weight-loss phenomenon by positioning Renuvion (RF-assisted liposuction) and AYON (radiofrequency skin tightening) as the aesthetic follow-up to pharmacological weight loss. As patients shed pounds via semaglutide and tirzepatide, loose skin becomes a cosmetic liability—and a practice revenue opportunity.
Devices & Tech
Apyx Sees GLP-1 Boom Fueling Body Contouring Demand
Renuvion and AYON positioned to capture post-weight-loss skin tightening surge.
1-YEAR MOVE
APYX
▲33.3%
| Ticker | Company | 1-year change |
|---|---|---|
| APYX | Apyx Medical (Renuvion) | +33.3% |
GLP-1 weight loss creates a new patient cohort with visible skin-quality concerns.
Renuvion's mechanism—radiofrequency energy applied during liposuction to simultaneously tighten skin—aligns perfectly with post-GLP-1 body contouring. AYON, a standalone RF device, addresses skin laxity without liposuction. Apyx's thesis is sound: GLP-1 adoption creates a new patient cohort with disposable income and visible skin-quality concerns. Practices offering both weight-loss support and body-contouring solutions can capture the full patient journey. The timing positions Apyx well against competitors still focused on facial aesthetics.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.